CTOs on the Move

Impel NeuroPharma

www.impelneuropharma.com

 
Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel`s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Impel NeuroPharma raised $36M on 12/02/2016
Impel NeuroPharma raised $67.5M on 12/06/2018

Similar Companies

Koya

Koya Medical is a transformative healthcare venture with a mission to treat cancer-related chronic lymphedema and venous diseases through innovative patient-centric platforms.

Meridian Medical Inc

Meridian Medical Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SHEN WEI (USA)

SHEN WEI (USA) is a Union City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prescient Surgical

Prescient Surgical, Inc. is a medical device innovator that makes advanced tools and technologies to fight and defend against the sources of surgical site infection.

Advanced Cardiac Therapeutics Inc

Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.